<code id='4DD53EDDAB'></code><style id='4DD53EDDAB'></style>
    • <acronym id='4DD53EDDAB'></acronym>
      <center id='4DD53EDDAB'><center id='4DD53EDDAB'><tfoot id='4DD53EDDAB'></tfoot></center><abbr id='4DD53EDDAB'><dir id='4DD53EDDAB'><tfoot id='4DD53EDDAB'></tfoot><noframes id='4DD53EDDAB'>

    • <optgroup id='4DD53EDDAB'><strike id='4DD53EDDAB'><sup id='4DD53EDDAB'></sup></strike><code id='4DD53EDDAB'></code></optgroup>
        1. <b id='4DD53EDDAB'><label id='4DD53EDDAB'><select id='4DD53EDDAB'><dt id='4DD53EDDAB'><span id='4DD53EDDAB'></span></dt></select></label></b><u id='4DD53EDDAB'></u>
          <i id='4DD53EDDAB'><strike id='4DD53EDDAB'><tt id='4DD53EDDAB'><pre id='4DD53EDDAB'></pre></tt></strike></i>

          focus

          focus

          author:hotspot    Page View:14
          Doctor holding a clipboard. -- health coverage from STAT
          Adobe

          The momentum around weight loss drugs is about to get even bigger in the wake of Novo Nordisk’s announcement that its semaglutide drug Wegovy cut the risk of cardiovascular disease by 20% in its large SELECT trial.

          The full results of the study, funded by Novo, will be presented at the American Heart Association meeting in November. Doctors and researchers say they expect the findings to have a big impact on how clinicians approach the treatment of both obesity and cardiovascular disease, as well as increase the likelihood that prescriptions for obesity drugs will be covered by insurance.

          advertisement

          But experts who spoke with STAT also cautioned that the long-term safety and efficacy of Wegovy and other weight loss drugs remain unknown. The SELECT study has yet to be peer-reviewed, and not enough information is yet available to make independent assessments of the results.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          Wikipedia

          Peter Hotez and the public health issue of online harassment
          Peter Hotez and the public health issue of online harassment

          AdobeFather’sDayweekendwasanythingbutcalmonTwitter,whicheruptedasvaccineexpertPeterHotezwaschallenge

          read more
          Morgan Health, with ambitious aims, wants you to know it’s still here
          Morgan Health, with ambitious aims, wants you to know it’s still here

          AdobeSANFRANCISCO—Almostthreeyearsago,thecountry’sbiggestbankunveiledaloftyplantofixthehealthcareind

          read more
          DIEP, the 'gold standard' of breast reconstruction, is under threat
          DIEP, the 'gold standard' of breast reconstruction, is under threat

          AdobeIn1983,Iflewhomefromcollegetobewithmymotherasshewokeupfromamastectomy.Sheoptedoutofbreastrecons

          read more

          Millions may soon lose Medicaid when they don't have to

          8:04Astheir5-year-olddaughterbattlesararegeneticdisorder,GillianandRockySapia,struggledtogettogetthe